Introduction
Recent progress in the treatment of various malignant diseases has enabled immunocompromised patients to survive considerably longer. However, there is a continuing increase worldwide in the number of patients with systemic fungal infections, particularly patients with complicated hematologic malignancies. Such individuals usually succumb within a short time unless effective antifungal chemotherapy and concomitant treatment of the underlying disease is prescribed. Systemic mycosis, including candidiasis, cryptococcosis, and aspergillosis, are being diagnosed with increasing frequency in acquired immunodeficiency syndrome (AIDS) patients. [1] [2] [3] [4] [5] Few comparative data on the susceptibility of strains isolated before, during, and after treatment are available.
This paper describes the data obtained by pulsed-field gel electrophoresis analysis in a fatal case of myelofibrosis complicated by recurrent candidemia that developed resistance during antifungal therapy. The pathologic findings at autopsy were myelofibrosis, systemic hemosiderosis, and systemic candidiasis. The candidal lesions detected were macroscopically characterized by many verrucae filling the lumen of the root of the pulmonary artery and on the right ventricle wall. The verrucae proved to consist of clusters of fungal elements. Diffuse candidal microabscesses were seen in the myocardium of the left ventricle, both lower lobes of the lungs, and the pleura. Candidal lesions were also seen in the liver, kidneys, and spleen. There was little evidence of an inflammatory change in these lesions, however, the culture of the candidal lesions was not examined at autopsy. Details of this case have already been reported in Clinical Infectious Disease.6) Susceptibility testing ( Fig. 1 ) C. albicans strains were repeatedly isolated from the patient's blood. The minimum inhibitory concentration (MIC) of antifungal agents for 10 strains of C. albicans isolated at various times during the clinical course was measured by standard susceptibility testing proposed by the National Committee for Clinical Laboratory Standards for yeast.7) The MIC of fluconazole for these strains increased from 0.125g/ml to over 64pg/ml after 40 days of therapy with a total dose of more than 6 g. Moreover, during the same period, the MICs of miconazole and itraconazole increased from 0.031g/ml to Bg/ml, and from 0.008g/ml to over 8g/ml, respectively, even though these drugs were not used in treatment. The MIC of amphotericin B gradually increased from 0.063 pg/ml to 0.5g/ml.
Materials
There was no change in MIC of flucytosine, which remained at 0.125ug/ ml after therapy.
Analysis of chromosomal DNAs The chromosomal DNA of five fluconazolesensitive C. albicans strains (nos. 1 through 5, MIC: 0.125g/ml) isolated during therapy in the first 4 weeks, five fluconazole-resistant C. albicans strains (nos. 6 through 10, MIC: >64 ug/ml) isolated during therapy in the second 7 weeks, and one Saccharomyces cerevisiae, strain was subjected to separation by pulsed-field gel electrophoresis using the methods of Merz et al.a) and (Fig. 2) . Genetic approaches have proved valuable in defining strains of S. cerevisiae with specific genotypes and determining linkage groups and chromosome numbers.
The chromosomal DNA of all sensitive and resistant strains showed similar patterns, with no differences observed between the 1.0 and 2.0 Mb medium band, except for the strains having >2.0 Mb-bands. No bands were demonstrated in resistant strains Nos. 7, 8, or 9, suggesting a multiplicity of molecular weights. Similarly, resistant strains Nos. 6, 9, and 10 showed larger molecular bands.
Discussion
Risk factors for nosocomial candidiasis include prior treatment with multiple antibiotics, the presence of a central line, bladder catheterization, isolation of Candida species from sites other than the blood, azotemia or prior hemodialysis, transfer from other hospitals, diarrhea, and so forth.10) 11) Particularly in patients with hematologic diseases, previous bacteremia, and prolonged neutropenia or fever, long-term antimicrobial therapy is jeopardized by serious risks of candidemia.12) In our patient, there were numerous risk factors prior to candidemia, including chemotherapy for myelofibrosis, multiple antimicrobial chemotherapy, indwelling intravenous catheters, prolonged neutropenia, and persistent fever unresponsive to broad-spectrum antibiotic therapy.
When administration of antibiotics permits overgrowth of Candida in the gastrointestinal tract, it may invade the intact or damaged intestinal mucosa 13) and may cause Candida sepsis. In our case, sepsis resulted from an overgrowth of the yeasts due to use of multiple and broad-spectrum antimicrobial agents, as well as the use of an intravenous catheter.
Concomitant fluconazole and intravenous amphotericin B therapy was administered to this patient, and his fever transiently subsided. However, fungemia recurred because the heart lesion could not be resected and the endocardial lesions persisted. The repeatedly isolated strains of C. albicans were believed to be the same species.
Fluconazole has frequently been used for oropharyngeal candidiasis for long periods, and there are increasing reports of fluconazole-resistant C. albicans infections. However, fluconazole-resistant Candida infection is rare except in AIDS patients.
Millon et a1.3) reported that fluconazoleresistant C. albicans (MIC: >32ug/ml) emerged after 90 days of treatment corresponding to a total dose of more than 10g. The MIC of fluconazole for C. albicans isolated from our patient increased after a 40-day course corresponding to a total dose of more than 6g. The MIC of amphotericin B for C. albicans was elevated after 70 days of treatment, corresponding to a total dose of more than 2g.
The reasons for the development of resistance to fluconazole and the elevation of the MIC of amphotericin B for C. albicans are not clear, but the dose and/or the duration of the antifungal therapy may have been responsible. 14) Thus, it would appear that azole resistance is an inevitable consequence of long-term therapy in permanently immunosuppressed patients.
Among patients with acquired immunodeficiency syndrome (AIDS) who might benefit from continuous antifungal agents for esophageal candidiasis, those receiving chemotherapy for mycobacterial infections seem to be more prone to recurrence than others.15) Rifampicin has been reported to induce the metabolism of fluconazole.16) In our case, however, the serum fluconazole level determined by high-performance liquid chromatography was 8g/ml, when the patient was given fluconazole at 200mg/day and rifampicin at 450 mg/day, in contrast to 16 to 17.2ug/ml when he was given fluconazole monotherapy at 400mg /day. Thus, no induction of fluconazole metabolism by rifampicin was observed. Further study is necessary to determine drug interactions during continuous, concomitant administration of antifungal agents and antimycobacterial agents.
It is generally believed that resistance can develop in clinical C. albicans isolates as a result of changes in permeability of the fungal cell wall, overexpression of different multidrug efflux transporter genes, or affinity alteration to azole antifungal agents through specific mutations of their target.
Acquired cross-resistance to azole antifungal agents is caused mainly by overexpression of a distinct multidrug efflux transporter gene, while intrinsic low levels of resistance to fluconazole seem to be due to the constitutive expression of another transporter gene. [17] [18] [19] [20] We used the pulsed-field gel electrophoresis method to elucidate the difference of karyotype between fluconazole-sensitive and fluconazoleresistant strains of C. albicans. The results showed the same karyotype among all strains isolated during the clinical course; there were no major differences in DNA profile. This suggests that the C. albicans strains isolated from our patient which were causing the continued fungemia and the strains that were sensitive to fluconazole therapy were closely related. These data showed that repeatedly isolated C. albicans were the same strain and acquired a resistance to antifungal agents during the therapy. Moreover, the presence of the new bands in strains Nos. 6, 9, and 10, and the lack of bands in strains loos. 7, 8, and 9 hinted at the effects of slight changes in DNA. These changes may suggest a mechanism of acquisition of resistance of C. albicans to these antifungal agents. However, these results were obtained by analyzing only one case, and further studies on resistance mechanisms will be necessary for confirmation.
